Altamira Therapeutics Attends H.C. Wainwright Conference 2024
Altamira Therapeutics to Present at Major Investment Conference
Hamilton, Bermuda — Altamira Therapeutics Ltd. (Nasdaq: CYTO), a trailblazer in the development of RNA delivery technologies, is set to make waves at the upcoming H.C. Wainwright 26th Annual Global Investment Conference. This event will take place both virtually and in person, allowing participants to engage in meaningful discussions.
Key Details of the Event
The presentation will be held on September 9, 2024, at 7:00 AM ET. This is a significant opportunity for Altamira's founder, Chairman, and CEO Thomas Meyer to highlight the company’s advancements in RNA delivery targeting beyond the liver.
What to Expect
Attendees will have access to the presentation on-demand, providing the chance to submit their questions directly to the Company. It's a platform designed for engagement, learning, and sharing insights about the exciting developments in the RNA delivery field.
About Altamira Therapeutics and Its Innovations
Altamira Therapeutics is pushing the boundaries of medicine with its innovative peptide-based nanoparticle technologies aimed at improving RNA delivery to non-liver tissues. Two of its flagship programs, AM-401 and AM-411, target KRAS-driven cancers and rheumatoid arthritis, respectively. Both are currently in preclinical phases, underlining the company’s commitment to advancing therapies that meet critical medical needs.
Strategic Partnerships and Future Directions
In addition to its RNA delivery platforms, Altamira holds a 49% stake in Altamira Medica AG, which encompasses its market-ready asset Bentrio®, a nasal spray designed for allergic rhinitis. The company is forging ahead to explore new partnerships and potential divestments of its inner ear legacy assets, which positions it favorably in the biotech landscape.
Company Vision and Goals
Founded in 2003, Altamira Therapeutics is headquartered in Hamilton, Bermuda, with significant operations in Basel, Switzerland. The Company is dedicated to revolutionizing RNA delivery systems and continues to explore licensing opportunities to support its initiatives. With a focus on innovative solutions, Altamira is poised to make a significant impact in the biotech sector.
Frequently Asked Questions
What is the H.C. Wainwright Conference?
The H.C. Wainwright Conference is an annual event that gathers leading companies in the investment space to showcase their innovations and engage with investors.
When will Altamira's presentation take place?
Altamira's presentation is scheduled for September 9, 2024, at 7:00 AM ET.
What technologies is Altamira focused on?
Altamira Therapeutics focuses on peptide-based nanoparticle technologies for RNA delivery to extrahepatic tissues.
What are AM-401 and AM-411?
AM-401 targets KRAS-driven cancers, while AM-411 aims to address rheumatoid arthritis, both in preclinical development.
How can I connect with Altamira Therapeutics?
To schedule a direct meeting with company representatives, it's recommended to send an email to their investor relations department.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Equature's 2024.3 Software Revolutionizes Public Safety Operations
- Jamie Foxx Brings Humor to BetMGM's 2024 Football Campaign
- Wipfli Unveils 2024 Annual Report Detailing Growth and Innovation
- Costco to Expand with Four New Locations by End of 2024
- Bloomberg CityLab 2024: Global Mayors Gather in Mexico City
- Blue Federal Credit Union Achieves Prestigious Awards in 2024
- Cambridge Launches Family Business Leadership Programme in 2024
- Allpowers Showcases Innovative Power Solutions at IFA 2024
- TEN, Ltd. Schedules Q2 2024 Results Event and Conference Call
- INmune Bio Inc. Joins Baird 2024 Global Healthcare Conference
- Plumas Bank Unveils 2024 Corporate Citizenship Insights
- Roper Technologies to Showcase Innovations at GS Conference
- Kronos Bio to Showcase Research at Key Medical Conferences
- Outlook Therapeutics to Present at Major Investment Conference
- NMI Holdings, Inc. Investor Day Scheduled for November 2024
- Alto Ingredients, Inc. to Present at H.C. Wainwright Conference
- LM Funding America, Inc. Gears Up for H.C. Wainwright Conference
- Femasys Highlights Innovation at H.C. Wainwright Conference
- Robinhood to Share Insights at Goldman Sachs Conference
- Avenue Therapeutics Announces Participation in Investor Conferences
- Cassava Sciences to Shine at H.C. Wainwright Conference
- Y-mAbs Therapeutics to Present at Key Investor Conferences
- Callinex Begins 2024 Exploration at Pine Bay Project Initiative
- Alexandria Real Estate Equities Announces Q3 2024 Results Call
- Indonesia Energy Prepares for H.C. Wainwright Conference Focus
Recent Articles
- Leinco Technologies Inc. Expands Portfolio with QED Biosciences
- Supermicro Addresses Concerns Over Annual Report Filing
- HomeSafe Alliance Achieves Milestone Of 100 Military Moves
- Former Central Bank Governor Riad Salameh Faces Arrest Over Fraud
- UC Asset LP Announces Management-Driven Stock Buyback Plan
- Farmers Face Financial Uncertainty Amid Declining Income
- Bevel Becomes Official Grooming Sponsor for CAU Alumni Event
- Yukon Metals Unveils Promising Gold and Copper Discovery
- Sustainable Apparel Market Projected to Hit USD 24.53 Billion
- Ignitis Group Greenlights 174 MW Solar Project in Latvia
- Ignitis Group Commits to 174 MW Tume Solar Project
- GeoVax Labs, Inc. Announces Upcoming Investor Events!
- Lake City Bank Enhances Warsaw Campus with New Center
- PTC Welcomes Rob Bernshteyn to the Board of Directors
- Keros Therapeutics Progresses in Phase 2 TROPOS Trial for PAH
- Pasithea Therapeutics Welcomes Dr. Rebecca Brown to Advisory Board
- CoinW Launches Innovative Futures Grid and CTA Tools for Traders
- Cognition Therapeutics: Upcoming Investor Conferences Insights
- Juli Saitz Appointed as Senior Managing Director at FTI Consulting
- Elevation Oncology Highlights Upcoming H.C. Wainwright Conference
- Axogen Grants Equity Award to New Employee Under NASDAQ Rule
- C4 Therapeutics Welcomes Stephen Fawell, Ph.D. to Leadership
- Jean Gattuso Takes Leadership as Chair of Letko Brosseau Board
- The Ensign Group Expands Portfolio with New Kansas Facility
- Blackwell 3D Advances Corporate Growth and Asian Expansion Plans